The indirect comparisons of efficacy between tofacitinib and control was marginally statistically significant at P < 0.05 in the NMA of all 16 trials and became significant after removing the 1 trial deemed high risk of bias.
← all excerpts
Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials.
1
0.0500
0.0500